Cytokinetics (CYTK) Gross Margin (2025 - 2026)
Cytokinetics (CYTK) posted quarterly Gross Margin of 99.17% for Q1 2026, down 83.0% year-over-year from 583.37% in Q1 2025, and down 0.83% quarter-over-quarter from 100.0% in Q1 2025.
Powered by 
Analysis
Cytokinetics (CYTK) Gross Margin (2025 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Gross Margin for 2 consecutive years, with 99.17% the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Cytokinetics | 9.63 Bn | 8.46 Bn | 25.89 Mn | 90.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 90.46% |
| Mar 31, 2026 | 99.17% |
| Jun 30, 2025 | 100.00% |
| Mar 31, 2025 | 100.00% |